Jul 31, 2009
By:
A. Nair
On July 18 in Mumbai, Hillary Rodham Clinton's private, cosy tete-a-tete with 10 of India Inc's most sought-after billionaires, was a power breakfast the likes of which the city's corporate czars had not seen in a long time.
|
Patent infringement claims and a lack of clear global trade distribution routes may be unraveling the country's generic-drug export industry.
Jun 11, 2009
By:
A. Nair
Patent infringement claims and a lack of clear global trade distribution routes may be unraveling the country's generic-drug export industry.
|
With the economy down and multinational firms capitalizing on patents in developing countries, India's R&D sector still has a long way to grow.
Mar 2, 2009
By:
A. Nair
With the economy down and multinational firms capitalizing on patents in developing countries, India's R&D sector still has a long way to grow.
|
While the world pulls itself out from one of the worst crises in decades, Indian pharmaceutical companies are trying to capitalize on falling company prices by increasing their takeovers.
Dec 2, 2008
By:
A. Nair
While the world pulls itself out from one of the worst crises in decades, Indian pharmaceutical companies are trying to capitalize on falling company prices by increasing their takeovers.
|
The Indian government may soon monopolize its pharmaceutical industry to cut costs and improve healthcare, but the move is sounding off alarm bells with the companies whose drug products are under review.
Nov 2, 2008
By:
A. Nair
The Indian government may soon monopolize its pharmaceutical industry to cut costs and improve healthcare, but the move is sounding off alarm bells with the companies whose drug products are under review.
|
Differential pricing is making more than just an appearance in Asia's pharma market these days.
Sep 2, 2008
By:
A. Nair
Differential pricing is making more than just an appearance in Asia's pharma market these days.
|
With rising drug deveopment costs and burdensome clinical trials, Indian-based firms are transferring their research departments to other entities in hopes of saving cash, mitigating risk, and ultimately, buying back the rewards.
Jun 2, 2008
By:
A. Nair
With rising drug deveopment costs and burdensome clinical trials, Indian-based firms are transferring their research departments to other entities in hopes of saving cash, mitigating risk, and ultimately, buying back the rewards.
|
Mar 2, 2008
By:
A. Nair
A. Nair discusses patent disputes in India.
|
Jan 2, 2008
By:
A. Nair
The $6.3 billion Indian pharmaceutical industry is at a crossroad. Aiming to be the international home for quality drugs, which could in itself propel India's market to $20 billion by 2015 according to recent estimates, the generic hothouse is clearly moving beyond its earlier low-cost mindset.
|
|
